HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Brama, M. Articles by Gnessi, L. Search for Related Content PubMed PubMed Citation Articles by Brama, M. Articles by Gnessi, L.

Department of Medical Physiopathology, University of Rome ‘La Sapienza’, Rome, Italy
¹ Cardiovascular Research Unit, Department of Medical Sciences, IRCCS San Raffaele, Roma, Tosinvest Sanità, Rome, Italy

(Requests for offprints should be addressed to L Gnessi who is now at Department of Medical Physiopathology, Policlinico Umberto I, Università di Roma ‘La Sapienza’, Roma, Italy; Email: lucio.gnessi{at}uniromal.it)

Inhibition of platelet-derived growth factor receptor (PDGFR) signaling restricts the growth of human breast cancer in the bone of nude mice. We hypothesized that osteoblast-secreted substances may alter the response capacity of breast cancer cells to the PDGFRs tyrosine kinase inhibitor imatinib mesylate. We found that osteoblast-conditioned medium (OCM) increases the proliferation rate of the estrogen receptor negative (ER–) MDA-MB-231 and of the ER+ MCF-7 human breast cancer cell lines and the growth-promoting effect on ER+ cells is independent from estrogen. OCM significantly improved the dose- and the time-dependent sensitivity of the tumor cells to the anti-proliferative effect of imatinib. We also found that MDA-MB-231 and MCF-7 cells express the two PDGFRs subtypes, PDGFR- and PDGFR-ß, and OCM treatment increases the expression of the PDGFRs. Furthermore, imatinib inhibited the phosphorylation rate of its target tyrosine kinase receptors. We conclude that bone microenvironment, through osteoblast-secreted substances may cause estrogen-independent proliferation of breast cancer cells by a mechanism mediated by the induction of PDGFRs expression. The enhanced sensitivity of OCM-treated breast cancer cells to imatinib would justify investigation on the efficacy of imatinib in bone breast cancer metastasis.

This article has been cited by other articles:

				L. Hu, Y. T. Zhu, C. Qi, and Y.-J. Zhu Identification of Smyd4 as a Potential Tumor Suppressor Gene Involved in Breast Cancer Development Cancer Res., May 1, 2009; 69(9): 4067 - 4072. [Abstract] [Full Text] [PDF]